CS0159 plus semaglutide for fatty liver and type 2 diabetes with obesity
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether combining two medications—CS0159 and semaglutide—can safely treat fatty liver disease, type 2 diabetes, and obesity together. If it works, it may help reduce liver fat and improve blood sugar control while supporting weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Fatty liver confirmed by MRI scan (at least 10% fat in liver) within last 3 months
- Type 2 diabetes diagnosis with blood sugar control managed only by diet and exercise for at least 3 months
- BMI (body mass index) between 30–45 kg/m²
- Recent blood work showing normal liver, kidney, and blood cell counts; no hepatitis, HIV, or certain infections
- Willing to keep diet and exercise consistent, take medication as directed, and check blood sugar regularly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.
This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.